With an initial investment of over 17 million euros for the development of 5,600 square meters of new laboratories dedicated to pharmaceutical technology and analytical chemistry, Alfasigma confirms its commitment to Research and Development. L’inauguration of ‘Labio 4.0 Marino Golinelli’, this morning in the Pomezia pharmaceutical group plant, is part of a broader corporate strategy of progressive investment in R&D, which allows Alfasigma, one of the top five pharmaceutical companies with Italian capital, to stand out both nationally and internationally for innovation and technological development.
Read Also
- After the school massacre, the governor of Texas will not attend the annual convention of the National Rifle Association May 27, 2022
- The fall from grace of Chino Enoch: from star paramilitary of the Ortega regime to a punishment cell May 29, 2022
- Toulouse: A former collaborator of the municipal majority sentenced for homophobic insult Nov 17, 2022
- Meghan Markle claims ‘women of influence’ begged her not to stop her activism Nov 20, 2022
- Strike of San Antonio dock workers comes to an end: they will resume functions this Friday Nov 25, 2022
- Orpea case: Why were several establishments of the group raided? Nov 16, 2022
- Ivana Yturbe showed the apartment where she will live with Beto da Silva and her daughter Jul 13, 2021